Research graph
References from Parkinson’s disease and chronic kidney disease trends and disparities in the US population aged over 25 years (1999–2023). Local targets link to admitted publications; unresolved targets remain external evidence.
Role of dopamine in the pathophysiology of Parkinson’s disease.
10.1186/s40035-023-00378-6 · 2023 · External reference
Alpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction.
10.1038/s41419-023-05672-9 · 2023 · External reference
Impact of environmental risk factors on mitochondrial dysfunction, neuroinflammation, protein misfolding, and oxidative stress in the etiopathogenesis of Parkinson’s disease.
10.3390/ijms231810808 · 2022 · External reference
National vital statistics reports.
2023 · External reference
Global, regional and national burden of Parkinson’s disease in people over 55 years of age: a systematic analysis of the global burden of disease study, 1991-2021.
10.1186/s12883-025-04191-8 · 2025 · External reference
Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
10.1016/s1474-4422(18)30295-3 · 2018 · External reference
Application of GFR estimation equations in elderly patients with measured GFR below 60 mL/min/1.73 m2.
10.1007/s40520-019-01218-2 · 2019 · External reference
The role of diabetes mellitus and hypertension in chronic kidney disease.
2014 · External reference
Epidemiology of chronic kidney disease: an update 2022.
10.1016/j.kisu.2021.11.003 · 2022 · External reference
Global burden of chronic kidney disease and its attributable risk factors (1990-2021): an analysis based on the global burden of disease study.
10.3389/fendo.2025.1563246 · 2025 · External reference
The health stage of cardiovascular-kidney-metabolic (CKM) syndrome is useful for predicting all-cause mortality in patients with type 2 diabetes: a cohort study in a period prior to the standard use of recent pharmacotherapy.
10.1016/j.jdiacomp.2025.109146 · 2025 · External reference
Propagation of pathologic α-synuclein from kidney to brain may contribute to Parkinson’s disease.
10.1038/s41593-024-01866-2 · 2025 · External reference
Racial Disparities in mortality trends from acute myeloid leukemia: a population-based study in the United States between 2000 and 2019.
10.1182/blood-2022-171171 · 2022 · External reference
The STROBE guidelines.
10.4103/sja.sja_543_18 · 2019 · External reference
Underlying and contributing causes of mortality from CDC WONDER—insights for researchers.
2025 · External reference
2013 NCHS urban-rural classification scheme for counties.
2014 · External reference
Age standardization of death rates: Implementation of the year 2000 standard.
1998 · External reference
Permutation tests for joinpoint regression with applications to cancer rates.
10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z · 2000 · External reference
Association between kidney function and Parkinson’s disease risk: a prospective study from the UK Biobank.
10.1186/s12889-024-19709-x · 2024 · External reference
Chronic kidney disease, proteinuria, and mortality risk in patients with Parkinson’s disease: a 12-year longitudinal study.
10.3389/fnagi.2025.1631079 · 2025 · External reference
The relationship between kidney health and neurodegenerative diseases.
10.1093/brain/awaf113 · 2025 · External reference
Parkinson’s disease and cardiovascular involvement: edifying insights (Review).
10.3892/br.2023.1607 · 2023 · External reference
Mortality in Parkinson’s disease: a systematic review and meta-analysis.
10.1002/mds.25898 · 2014 · External reference
Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?
10.1093/ndt/gfab223 · 2021 · External reference
Frailty and physical function in chronic kidney disease: the CanFIT study.
10.1186/s40697-015-0067-4 · 2015 · External reference
Falls in Parkinson’s disease: the impact of disease progression, treatment, and motor complications.
10.1590/1980-5764-dn-2021-0019 · 2022 · External reference
Risk factors for hip and vertebral fractures in chronic kidney disease: the CRIC study.
10.1093/jbmr/zjae021 · 2024 · External reference
Mineral bone disorders in kidney disease patients: the ever-current topic.
10.3390/ijms232012223 · 2022 · External reference
Prevalence of malnutrition in patients with Parkinson’s Disease: a systematic review.
10.3390/nu14235194 · 2022 · External reference
Kidney cachexia or protein‐energy wasting in chronic kidney disease: facts and numbers.
10.1002/jcsm.12421 · 2019 · External reference
Effects of renal impairment on the pharmacokinetics of once-daily amantadine extended-release tablets.
10.1007/s40263-019-00651-1 · 2019 · External reference
A comprehensive review of the diagnosis and treatment of Parkinson’s disease dysphagia and aspiration.
10.1080/17474124.2020.1769475 · 2020 · External reference
Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association.
10.1093/cvr/cvad083 · 2023 · External reference
Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden.
10.1053/j.ackd.2008.01.010 · 2008 · External reference
The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease.
10.1038/sj.ki.5001934 · 2006 · External reference
How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: comparison with the unified Parkinson’s disease rating scale.
10.1002/mds.25383 · 2013 · External reference
Dapagliflozin in patients with chronic kidney disease.
10.1056/nejmoa2024816 · 2020 · External reference
Chronic kidney disease and cognitive impairment: the kidney-brain axis.
10.1159/000524475 · 2022 · External reference
The nephrology crystal ball: the medium-term future.
10.1093/ndt/gfz199 · 2020 · External reference
Towards a methodological uniformization of environmental risk studies in Parkinson’s disease.
10.1038/s41531-024-00709-y · 2024 · External reference
Association between heavy metal exposure and Parkinson’s disease: a review of the mechanisms related to oxidative stress.
10.3390/antiox11122467 · 2022 · External reference
Integrating palliative care in Parkinson’s Disease and related disorders: a systematic review of patient and caregiver outcomes.
10.1177/10499091251393691 · 2025 · External reference
Accuracy of death certificates and assessment of factors for misclassification of underlying cause of death.
10.2188/jea.je20150010 · 2016 · External reference
National trends and demographic disparities in mortality involving co-recorded Parkinson’s disease and dementia in the United States, 1999-2025: a CDC WONDER analysis.
10.3390/neurosci7030066 · 2026 · External reference
Competing risk of death: an important consideration in studies of older adults.
10.1111/j.1532-5415.2010.02767.x · 2010 · External reference
Age-period-cohort models in cancer surveillance research: ready for prime time?
10.1158/1055-9965.epi-11-0421 · 2011 · External reference
Permutation tests for joinpoint regression with applications to cancer rates.
10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z · ExternalCitation · doi-reference
Kidney cachexia or protein‐energy wasting in chronic kidney disease: facts and numbers.
10.1002/jcsm.12421 · ExternalCitation · doi-reference
How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: comparison with the unified Parkinson’s disease rating scale.
10.1002/mds.25383 · ExternalCitation · doi-reference
Mortality in Parkinson’s disease: a systematic review and meta-analysis.
10.1002/mds.25898 · ExternalCitation · doi-reference
Effects of renal impairment on the pharmacokinetics of once-daily amantadine extended-release tablets.
10.1007/s40263-019-00651-1 · ExternalCitation · doi-reference
Application of GFR estimation equations in elderly patients with measured GFR below 60 mL/min/1.73 m2.
10.1007/s40520-019-01218-2 · ExternalCitation · doi-reference
The health stage of cardiovascular-kidney-metabolic (CKM) syndrome is useful for predicting all-cause mortality in patients with type 2 diabetes: a cohort study in a period prior to the standard use of recent pharmacotherapy.
10.1016/j.jdiacomp.2025.109146 · ExternalCitation · doi-reference
Epidemiology of chronic kidney disease: an update 2022.
10.1016/j.kisu.2021.11.003 · ExternalCitation · doi-reference
Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
10.1016/s1474-4422(18)30295-3 · ExternalCitation · doi-reference
Alpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction.
10.1038/s41419-023-05672-9 · ExternalCitation · doi-reference
Towards a methodological uniformization of environmental risk studies in Parkinson’s disease.
10.1038/s41531-024-00709-y · ExternalCitation · doi-reference
Propagation of pathologic α-synuclein from kidney to brain may contribute to Parkinson’s disease.
10.1038/s41593-024-01866-2 · ExternalCitation · doi-reference
The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease.
10.1038/sj.ki.5001934 · ExternalCitation · doi-reference
Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden.
10.1053/j.ackd.2008.01.010 · ExternalCitation · doi-reference
Dapagliflozin in patients with chronic kidney disease.
10.1056/nejmoa2024816 · ExternalCitation · doi-reference
A comprehensive review of the diagnosis and treatment of Parkinson’s disease dysphagia and aspiration.
10.1080/17474124.2020.1769475 · ExternalCitation · doi-reference
The relationship between kidney health and neurodegenerative diseases.
10.1093/brain/awaf113 · ExternalCitation · doi-reference
Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association.
10.1093/cvr/cvad083 · ExternalCitation · doi-reference
Risk factors for hip and vertebral fractures in chronic kidney disease: the CRIC study.
10.1093/jbmr/zjae021 · ExternalCitation · doi-reference
Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?
10.1093/ndt/gfab223 · ExternalCitation · doi-reference
The nephrology crystal ball: the medium-term future.
10.1093/ndt/gfz199 · ExternalCitation · doi-reference
Competing risk of death: an important consideration in studies of older adults.
10.1111/j.1532-5415.2010.02767.x · ExternalCitation · doi-reference
Age-period-cohort models in cancer surveillance research: ready for prime time?
10.1158/1055-9965.epi-11-0421 · ExternalCitation · doi-reference
Chronic kidney disease and cognitive impairment: the kidney-brain axis.
10.1159/000524475 · ExternalCitation · doi-reference
Integrating palliative care in Parkinson’s Disease and related disorders: a systematic review of patient and caregiver outcomes.
10.1177/10499091251393691 · ExternalCitation · doi-reference
Racial Disparities in mortality trends from acute myeloid leukemia: a population-based study in the United States between 2000 and 2019.
10.1182/blood-2022-171171 · ExternalCitation · doi-reference
Global, regional and national burden of Parkinson’s disease in people over 55 years of age: a systematic analysis of the global burden of disease study, 1991-2021.
10.1186/s12883-025-04191-8 · ExternalCitation · doi-reference
Association between kidney function and Parkinson’s disease risk: a prospective study from the UK Biobank.
10.1186/s12889-024-19709-x · ExternalCitation · doi-reference
Role of dopamine in the pathophysiology of Parkinson’s disease.
10.1186/s40035-023-00378-6 · ExternalCitation · doi-reference
Frailty and physical function in chronic kidney disease: the CanFIT study.
10.1186/s40697-015-0067-4 · ExternalCitation · doi-reference
Falls in Parkinson’s disease: the impact of disease progression, treatment, and motor complications.
10.1590/1980-5764-dn-2021-0019 · ExternalCitation · doi-reference
Accuracy of death certificates and assessment of factors for misclassification of underlying cause of death.
10.2188/jea.je20150010 · ExternalCitation · doi-reference
Global burden of chronic kidney disease and its attributable risk factors (1990-2021): an analysis based on the global burden of disease study.
10.3389/fendo.2025.1563246 · ExternalCitation · doi-reference
Chronic kidney disease, proteinuria, and mortality risk in patients with Parkinson’s disease: a 12-year longitudinal study.
10.3389/fnagi.2025.1631079 · ExternalCitation · doi-reference
Association between heavy metal exposure and Parkinson’s disease: a review of the mechanisms related to oxidative stress.
10.3390/antiox11122467 · ExternalCitation · doi-reference
Impact of environmental risk factors on mitochondrial dysfunction, neuroinflammation, protein misfolding, and oxidative stress in the etiopathogenesis of Parkinson’s disease.
10.3390/ijms231810808 · ExternalCitation · doi-reference
Mineral bone disorders in kidney disease patients: the ever-current topic.
10.3390/ijms232012223 · ExternalCitation · doi-reference
National trends and demographic disparities in mortality involving co-recorded Parkinson’s disease and dementia in the United States, 1999-2025: a CDC WONDER analysis.
10.3390/neurosci7030066 · ExternalCitation · doi-reference
Prevalence of malnutrition in patients with Parkinson’s Disease: a systematic review.
10.3390/nu14235194 · ExternalCitation · doi-reference
Parkinson’s disease and cardiovascular involvement: edifying insights (Review).
10.3892/br.2023.1607 · ExternalCitation · doi-reference
The STROBE guidelines.
10.4103/sja.sja_543_18 · ExternalCitation · doi-reference
